Print Page

给 医 护 专 业 人 员 的 信
 
Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics (Letter to Healthcare Professionals) (English Only)
 
 
 
附件:
  1. Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics  
Related Information:
Canada: Benzocaine products should not be used in children under two years of ag... 上载于 2020-10-16
美国：严重及潜在致命血液疾病的风险促使美国食物及药物管理局对用于出牙及口腔疼痛的口腔用非处方苯佐卡因产品和处方局部麻醉剂采取行动 上载于 2018-05-24
加拿大：含苯佐卡因产品的标签将添加新的风险声明，以提供有关高铁血红蛋白血症风险及提醒服用最少剂量的补充资讯。 上载于 2012-04-10
中国: 国家食品药品监督管理局对外用药苯佐卡因等三种药品说明书进行修订 上载于 2011-12-30
Singapore: Benzocaine and the risk of methaemoglobinaemia (English Only) 上载于 2011-08-05
中国：国家食品药品监督管理局提醒关注苯佐卡因引起高铁血红蛋白血症的安全性资讯 上载于 2011-07-14
Canada: Health Canada reminds Canadians of health risks associated with topical ... 上载于 2011-04-20
The United States: Benzocaine Topical Products: Sprays, Gels and Liquids - Risk ... 上载于 2011-04-08
小心使用含苯佐卡因药剂制品 上载于 2011-04-08
 
back